跳到正文
原文
Medical Xpress·· 2026-10-09精选AI 评分84

NRG-BR002 随机试验:寡转移乳腺癌一线系统治疗加用转移灶消融未改善生存

Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival

AI 导读

随机 II/III 期 NRG-BR002 试验显示,寡转移乳腺癌一线系统治疗加用放疗或手术消融转移灶,未改善无进展生存期和总生存期,结果发表于 Journal of Clinical Oncology。

推荐理由

系统性治疗基础上对寡转移灶加用放疗或手术未改善生存的随机试验结果,可为医患权衡是否加做局部治疗提供直接参照。

正文 · 原文
breast cancer
Credit: Pixabay/CC0 Public Domain

Treating individual metastatic tumors with highly focused radiation or surgery did not improve progression-free or overall survival for patients with oligometastatic breast cancer receiving first-line systemic therapy, according to results from the randomized NRG-BR002 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

The study, led by Steven Chmura, chair of Breast Radiation Oncology, was published this week in the Journal of Clinical Oncology. The findings provide important evidence against routinely adding metastasis-directed treatment for patients with a limited number of breast cancer metastases when effective systemic therapy is already controlling the disease.

Oligometastatic cancer refers to metastatic disease that has spread beyond the original tumor but remains confined to a small number of sites. Advances in stereotactic body radiation therapy (SBRT) and surgery have made it possible to eradicate individual metastases, which raises the following question: Could treating every visible site of disease delay progression or extend survival? Researchers designed this trial to directly test that approach in breast cancer.

"There has been tremendous interest in whether aggressively treating every visible metastatic site could change the natural history of breast cancer for patients with only a few metastases," Chmura said. "This randomized trial gives us important evidence that, for most patients in this setting, adding local treatment to effective systemic therapy does not improve progression-free or overall survival."

Why doesn't treating every visible metastasis improve outcomes in patients with oligometastatic breast cancer?

Although radiation or surgery can control individual metastases, the trial found that treating all visible metastases did not prevent new metastases from developing elsewhere. This suggests that eliminating visible tumors alone may not be enough to change the overall course of metastatic breast cancer.

The phase 2/3 NRG-BR002 trial enrolled 129 patients at 47 institutions across the United States and Canada, with 125 patients eligible for analysis. Participants had four or fewer metastatic lesions and were randomly assigned to receive either first-line systemic therapy alone or systemic therapy plus treatment of all known metastatic sites with SBRT or surgery.

The study did not meet its primary endpoint. Median progression-free survival was 23 months with systemic therapy alone compared with 19.5 months with metastasis-directed ablation, and overall survival also did not differ significantly between the groups. Because the trial did not show the required improvement in progression-free survival, it did not proceed to phase 3.

Longer follow-up reinforced the findings, showing no significant improvement in progression-free survival and no evidence that ablation reduced the development of new metastases.

Should radiation or surgery be added routinely to systemic therapy?

Based on these results, the researchers concluded that metastasis-directed SBRT or surgery should not be added routinely to first-line systemic therapy for oligometastatic breast cancer outside of clinical trials. Local treatment still has an important role when needed to relieve symptoms, such as pain or other problems caused by an individual metastatic lesion.

"More treatment is not always better treatment. These findings can help patients and physicians have clearer conversations about the expected benefit of additional radiation or surgery and potentially spare patients from treatments that add time, cost and potential side effects without improving survival," Chmura said.

Could some patients still benefit from metastasis-directed treatment?

An exploratory analysis led by Wendy A. Woodward, professor of breast radiation oncology, found that patients with no or very low levels of tumor cells circulating in their blood before treatment were more likely to benefit from targeted treatment of oligometastases. These patients went longer without their cancer getting worse, while patients with higher levels of circulating tumor cells did not see the same benefit.

The findings suggest that simply counting the number of places breast cancer has spread may not be enough to determine who should receive this aggressive treatment. In the future, blood-based markers such as circulating tumor cells and circulating tumor DNA could help doctors better identify which patients are most likely to benefit. Chelain Goodman, assistant professor of breast radiation oncology, is leading the next generation of clinical trials incorporating this approach.

Publication details

Steven J. Chmura et al, NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer, Journal of Clinical Oncology (2026). DOI: 10.1200/jco-26-00201

Journal information: Journal of Clinical Oncology

Clinical categories

Oncology

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-randomized-trial-individual-metastases-oligometastatic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com